Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen J Lachmann

Showing results (31-40 of 214) with videos related to

Pageof 22
Sort By:
Rheumatology (Oxford, England)|December 15, 2010
Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari syndrome and polyarteritis nodosaAriane S I Standing, Despina Eleftheriou, Helen J Lachmann, et al.
Nature Clinical Practice. Cardiovascular Medicine|December 17, 2008
Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutationAshutosh D Wechalekar, Mark Offer, Julian D Gillmore, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 27, 2017
Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiologyThirusha Lane, Ashutosh D Wechalekar, Julian D Gillmore, et al.
Haematologica|February 5, 2008
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal diseaseAshutosh D Wechalekar, Helen J Lachmann, Mark Offer, et al.
Clinical and Experimental Rheumatology|June 30, 2015
Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literatureThirusha Lane, Julian D Gillmore, Ashutosh D Wechalekar, et al.
Practical Neurology|March 12, 2016
Trapped without a diagnosis: Tumour necrosis factor receptor-associated periodic syndrome (TRAPS)Ali Kirresh, Alex Everitt, Onn Min Kon, et al.
Rheumatology Advances in Practice|September 1, 2021
COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologicsClaire J Peet, Charalampia Papadopoulou, Bella Ruth M Sombrito, et al.
Haematologica|May 25, 2011
Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosisAshutosh D Wechalekar, Julian D Gillmore, Nancy Wassef, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with AnakinraHelen J Lachmann, Renée J G Arnold, Marco Gattorno, et al.
Annals of the Rheumatic Diseases|August 14, 2018
Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi studyEldad Ben-Chetrit, Marco Gattorno, Ahmet Gul, et al.
Pageof 22

Showing results (31-40 of 214) with videos related to

Sort By:
Pageof 22
Rheumatology (Oxford, England)|December 15, 2010
Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari syndrome and polyarteritis nodosaAriane S I Standing, Despina Eleftheriou, Helen J Lachmann, et al.
Nature Clinical Practice. Cardiovascular Medicine|December 17, 2008
Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutationAshutosh D Wechalekar, Mark Offer, Julian D Gillmore, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 27, 2017
Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiologyThirusha Lane, Ashutosh D Wechalekar, Julian D Gillmore, et al.
Haematologica|February 5, 2008
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal diseaseAshutosh D Wechalekar, Helen J Lachmann, Mark Offer, et al.
Clinical and Experimental Rheumatology|June 30, 2015
Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literatureThirusha Lane, Julian D Gillmore, Ashutosh D Wechalekar, et al.
Practical Neurology|March 12, 2016
Trapped without a diagnosis: Tumour necrosis factor receptor-associated periodic syndrome (TRAPS)Ali Kirresh, Alex Everitt, Onn Min Kon, et al.
Rheumatology Advances in Practice|September 1, 2021
COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologicsClaire J Peet, Charalampia Papadopoulou, Bella Ruth M Sombrito, et al.
Haematologica|May 25, 2011
Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosisAshutosh D Wechalekar, Julian D Gillmore, Nancy Wassef, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with AnakinraHelen J Lachmann, Renée J G Arnold, Marco Gattorno, et al.
Annals of the Rheumatic Diseases|August 14, 2018
Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi studyEldad Ben-Chetrit, Marco Gattorno, Ahmet Gul, et al.
Pageof 22